Aardvark Therapeutics (AARD) vs Incannex Healthcare (IXHL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Incannex Healthcare (IXHL) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 80.3% versus a loss of 90.2%. Incannex Healthcare is the larger company by market cap ($23.3 million vs $20.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | IXHL |
|---|---|---|
| Share price | $0.9226 | $1.86 |
| Market cap | $20.20M | $23.34M |
| 1-day change | -7.74% | +6.90% |
| YTD return | -92.97% | -82.68% |
| 1-year return | -90.15% | -80.32% |
| EPS (TTM) | $-3.33 | $-1.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-57.59M | $-19.30M |
| 52-week high | $16.60 | $14.91 |
| 52-week low | $0.90 | $1.61 |
| Distance from 52-week high | -94.44% | -87.53% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +1104.21% | +904.30% |
| Average volume | 643.53K | 91.61K |
| Shares outstanding | 21.89M | 12.55M |
| Employees | 28 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Incannex Healthcare
IXHL stock →Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
AARD vs IXHL FAQ
Which is bigger, Aardvark Therapeutics or Incannex Healthcare?
Incannex Healthcare (IXHL) is larger, with a market capitalization of $23.34M compared with $20.20M for Aardvark Therapeutics (AARD).
Which stock has performed better over the past year, AARD or IXHL?
IXHL returned -80.32% over the past 12 months, compared with -90.15% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Incannex Healthcare in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.